BR9915694A - Composições compreendendo cefuroxima axetil - Google Patents

Composições compreendendo cefuroxima axetil

Info

Publication number
BR9915694A
BR9915694A BR9915694-6A BR9915694A BR9915694A BR 9915694 A BR9915694 A BR 9915694A BR 9915694 A BR9915694 A BR 9915694A BR 9915694 A BR9915694 A BR 9915694A
Authority
BR
Brazil
Prior art keywords
cefuroxime axetil
compositions
axetil
production
cefuroxime
Prior art date
Application number
BR9915694-6A
Other languages
English (en)
Inventor
Herwig Jennewein
Johannes Raneburger
Original Assignee
Biochemie Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biochemie Gmbh filed Critical Biochemie Gmbh
Publication of BR9915694A publication Critical patent/BR9915694A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçõES COMPREENDENDO CEFUROXIMA AXETIL"<D>. Cefuroxima axetil em uma forma não-gelatinosa em contato com um líquido aquoso, por exemplo na forma de uma solução sólida em um polímero ou na forma de uma dispersão sólida sobre um veículo, por exemplo útil para a produção de composições farmacêuticas compreendendo cefuroxima axetil como ingrediente ativo e o uso de cefuroxima axetil na produção de uma forma de dosagem oral que não apresenta efeito alimentar adverso.
BR9915694-6A 1998-11-26 1999-11-24 Composições compreendendo cefuroxima axetil BR9915694A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0198998A AT413647B (de) 1998-11-26 1998-11-26 Verwendung eines copolymerisats aus 1-vinyl-2-pyrrolidon und vinylacetat zur herstellung von cefuroximaxetil-hältigen tabletten
PCT/EP1999/009096 WO2000030647A1 (en) 1998-11-26 1999-11-24 Compositions comprising cefuroxime axetil

Publications (1)

Publication Number Publication Date
BR9915694A true BR9915694A (pt) 2001-08-14

Family

ID=3525440

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915694-6A BR9915694A (pt) 1998-11-26 1999-11-24 Composições compreendendo cefuroxima axetil

Country Status (30)

Country Link
US (1) US6727243B1 (pt)
EP (1) EP1133298B1 (pt)
JP (1) JP2002530338A (pt)
KR (1) KR20010080566A (pt)
CN (1) CN1330546A (pt)
AR (1) AR021405A1 (pt)
AT (3) AT413647B (pt)
AU (1) AU759517B2 (pt)
BR (1) BR9915694A (pt)
CA (1) CA2348876A1 (pt)
CO (1) CO5190668A1 (pt)
CZ (1) CZ20011845A3 (pt)
DE (1) DE69935609T2 (pt)
ES (1) ES2285866T3 (pt)
HU (1) HUP0104412A3 (pt)
ID (1) ID28615A (pt)
IL (1) IL142762A0 (pt)
MY (1) MY129564A (pt)
NO (1) NO20012526D0 (pt)
NZ (1) NZ511588A (pt)
PE (1) PE20001326A1 (pt)
PL (1) PL348744A1 (pt)
RU (1) RU2248794C2 (pt)
SI (1) SI1133298T1 (pt)
SK (1) SK7162001A3 (pt)
TR (1) TR200101417T2 (pt)
TW (1) TWI229603B (pt)
WO (1) WO2000030647A1 (pt)
YU (1) YU34601A (pt)
ZA (1) ZA200103927B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100342943B1 (ko) * 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물
US7527807B2 (en) * 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
AU2001230490A1 (en) * 2000-12-01 2002-06-11 Arun Shriniwas Gosavi Pharmaceutical formulation
EP1911462A3 (en) * 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US6524617B1 (en) * 2001-07-25 2003-02-25 Isp Investments Inc. Synergistic filler composition
MY148466A (en) 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
ES2201932B2 (es) * 2001-11-23 2005-03-16 Glaxo Group Limited Composicion farmaceutica.
JP4526247B2 (ja) * 2002-07-08 2010-08-18 第一三共株式会社 経口用セファロスポリン製剤
TW200404550A (en) * 2002-07-08 2004-04-01 Sankyo Co Cepharospolin formulation for oral use
AU2003260803A1 (en) * 2002-08-30 2004-03-19 Orchid Chemicals And Pharmaceuticals Ltd. Sustained release pharmaceutical composition
WO2005002540A2 (en) * 2003-07-01 2005-01-13 Ranbaxy Laboratories Limited Dry powder pharmaceutical suspension compositions of cefuroxime axetil
KR100552567B1 (ko) * 2003-08-23 2006-02-15 한국유나이티드제약 주식회사 수분 흡수에 안정하고 빠르게 붕해되는 세푸록심 악세틸을포함하는 정제의 조성물 및 제조 방법
NZ580951A (en) * 2005-04-29 2011-06-30 Cubist Pharm Inc Therapeutic compositions
CN100402035C (zh) * 2005-07-07 2008-07-16 石药集团中奇制药技术（石家庄）有限公司 一种微囊化头孢呋辛酯的药物组合物
CA2800444C (en) 2010-06-14 2018-03-20 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition
EP2882423A1 (en) * 2012-08-07 2015-06-17 Sandoz AG Uncoated tablet comprising granules including a -lactam antibiotic and highly dispersed silicone dioxide
JP5700740B1 (ja) 2013-04-25 2015-04-15 杏林製薬株式会社 固形医薬組成物
JP5651812B1 (ja) 2013-04-25 2015-01-14 杏林製薬株式会社 固形医薬組成物
US10154993B2 (en) 2014-10-23 2018-12-18 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1572993A (en) * 1976-02-16 1980-08-13 Glaxo Operations Ltd Ester derivatives of cefuroxime
GB1571683A (en) * 1976-02-16 1980-07-16 Glaxo Operations Ltd Ester derivatives of cefuroxime
YU44680B (en) * 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
GB8524001D0 (en) * 1985-09-30 1985-11-06 Glaxo Group Ltd Pharmaceutical composition
IL85538A (en) * 1987-02-27 1991-09-16 Lilly Co Eli Sustained release matrix tablet formulations containing hydrophilic and enteric polymers
NL193682C (nl) 1987-05-14 2000-07-04 Glaxo Group Ltd Beklede cefuroximaxetilsamenstelling.
DE3810343A1 (de) * 1988-03-26 1989-10-05 Basf Ag Verfahren zur herstellung von festen pharmazeutischen retardformen
DE4139963A1 (de) * 1991-12-04 1993-06-09 Basf Ag, 6700 Ludwigshafen, De Redispergierbares dispersionspulver aus n-vinylpyrrolidon-vinylacetat-copolymerisat, dessen herstellung und verwendung
DE19602757A1 (de) * 1996-01-26 1997-07-31 Boehringer Mannheim Gmbh Feste Instant-Release-Darreichungsformen und Verfahren zu ihrer Herstellung
US5663258A (en) * 1996-02-20 1997-09-02 Isp Investments Inc. Strongly swellable, moderately crosslinked copolymers of vinylpyrrolidone and vinyl acetate
DE19631085A1 (de) * 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Maleinsäure-Copolymeren zur Verbesserung der Permeabilität der Schleimhaut
PL191399B1 (pl) * 1996-10-28 2006-05-31 Gen Mills Inc Sposób kapsułkowania lub osadzania składnika w osnowie w procesie ciągłym, sposób kapsułkowania i/lub osadzania składników w osnowie opartej na węglowodanach, sposób kapsułkowania i/lub osadzania składników w osnowie oraz kapsułka
IL119627A (en) * 1996-11-17 2002-03-10 Yissum Res Dev Co PHARMACEUTICAL PREPARATIONS FOR THE CONTROLLED-RELEASE OF AN ACTIVE AGENT COMPRISING AT LEAST ONE β-LACTAM ANTIBIOTIC AGENT
CA2209868C (en) 1997-08-15 2001-08-14 Bernard Charles Sherman Pharmaceutical compositions comprising cefuroxime axetil
CA2322432C (en) * 1998-03-03 2005-12-20 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical composition containing cefuroxime axetil stable for moisture absorption
CA2239331C (en) 1998-05-29 1999-11-30 Bernard Charles Sherman Pharmaceutical tablets comprising cefuroxime axetil
DE19835823A1 (de) 1998-08-10 1999-10-07 Lindopharm Gmbh Pharmazeutische Zusammensetzung, Verfahren zu ihrer Herstellung und ihre Verwendung sowie aus ihr hergestellte wässerige Suspension
KR100342943B1 (ko) 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물

Also Published As

Publication number Publication date
DE69935609D1 (de) 2007-05-03
AT413647B (de) 2006-04-15
PE20001326A1 (es) 2000-12-12
YU34601A (sh) 2004-09-03
CA2348876A1 (en) 2000-06-02
SI1133298T1 (sl) 2007-10-31
WO2000030647A1 (en) 2000-06-02
AU1654400A (en) 2000-06-13
PL348744A1 (en) 2002-06-03
MY129564A (en) 2007-04-30
RU2248794C2 (ru) 2005-03-27
US6727243B1 (en) 2004-04-27
KR20010080566A (ko) 2001-08-22
AR021405A1 (es) 2002-07-17
SK7162001A3 (en) 2001-10-08
ES2285866T3 (es) 2007-11-16
CZ20011845A3 (cs) 2001-08-15
AT500135A1 (de) 2005-11-15
EP1133298A1 (en) 2001-09-19
CN1330546A (zh) 2002-01-09
HUP0104412A3 (en) 2002-08-28
NO20012526L (no) 2001-05-23
DE69935609T2 (de) 2007-12-06
ATE357237T1 (de) 2007-04-15
NZ511588A (en) 2003-08-29
JP2002530338A (ja) 2002-09-17
IL142762A0 (en) 2002-03-10
NO20012526D0 (no) 2001-05-23
AU759517B2 (en) 2003-04-17
ID28615A (id) 2001-06-21
ATA198998A (de) 2005-09-15
TR200101417T2 (tr) 2001-11-21
CO5190668A1 (es) 2002-08-29
EP1133298B1 (en) 2007-03-21
ZA200103927B (en) 2002-05-15
TWI229603B (en) 2005-03-21
HUP0104412A2 (hu) 2002-04-29

Similar Documents

Publication Publication Date Title
BR9915694A (pt) Composições compreendendo cefuroxima axetil
BR9910113A (pt) Composições oftálmicas que se transformam em gel, contendo goma xantano
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
BR9900320A (pt) Composição antimicrobiana
DE60104206D1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
BR0011433A (pt) Imidazoquinolinas substituìdas com sulfonamida e sulfamida
BR0112495A (pt) Forma de dosagem, processo para a produção de uma forma de dosagem e uso da forma de dosagem
BR0107147A (pt) Composições farmacêuticas de drogas anti-tuberculosas e processo para as suas preparações
BR0112962B1 (pt) Composições farmacêuticas compreendendo ácido hialurônico, ácido glicirretínico e polivinilpirrolidona, e uso desses compostos na preparação de medicamentos
DK1372608T3 (da) Medicinske aerosolformuleringer
ES2190246T3 (es) Nuevos compuestos de tiazolopirimidina.
BR0213355A (pt) composições farmacêuticas
SV2002000776A (es) Nuevas imidazotriazinonas sustituidas ref.lea 34 985-sv
BRPI0419048A (pt) composição útil para fornecer revestimento de remoção de nox sobre a superfìcie material
BR0302453A (pt) Composição de resposta deflagrada, e, processo para deflagrar a liberação de um ou mais ingredientes ativos a um sistema aquoso
ES2011232A4 (es) Compuestos farmaceuticos en piroxicam en soluciones acuosas y proceso para su preparacion
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
HK1038179A1 (en) New oral formulation for 5-ht4 agonists or antagonists
BR9810433A (pt) Composições anti-helmìnticas
EA200100802A1 (ru) Применение тианептина при приготовлении лекарственных средств, предназначенных для лечения нейродегенеративных патологий
BR0002772A (pt) Uso de ligantes melatoninérgicos na obtenção de composições farmacêuticas pretendidas para a prevenção ou o tratamento de patologias do sistema gastrintestinal
BR0011845A (pt) Complexo farmacêutico
BRPI0417796A (pt) preparado efervescente de uma substáncia básica de efeito medicinal
BR0214487A (pt) Composição farmacêutica que compreende uma combinação de metformina e um ácido 4-oxobutanóico, e o uso da mesma para o tratamento de diabetes
TR200003451T2 (tr) Pirimidin-Aminometil-Piridin Türevleri, Hazırlanmaları ve helikobakter bakterinin kontrolünde kullanımları

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.